REGENXBIO Inc. (Nasdaq: RGNX) today announced it will initiate a pivotal Phase IIb/III clinical trial for investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) ...

In patients with diabetic macular edema in both eyes, the port delivery system in one eye achieves a superior anatomical ...

With an increased focus on proactive care, Intermountain Health has made significant strides in the past year to expand ...

An intravitreal implant shows promise in enhancing visual function and retinal structure in diabetic retinopathy patients, according to recent research.

PER-001, delivered through a slow-release, dissolvable implant in the vitreous cavity of the eye, is designed to block ...

Diabetic retinopathy remains a major cause of vision loss among working-age individuals worldwide. While chronic ...

In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ...

Exonate has announced plans to initiate a phase 2b clinical trial of its lead candidate EXN407, a topical SRPK1 inhibitor, ...

Statistical analysis showed a strong association between advanced diabetic retinopathy and an increased likelihood of heart ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

As India grapples with an escalating diabetes crisis, with 101 million1 diagnosed and 136 million with pre-diabetes, the ...

The prevalence of cataract, responsible for 66.2% of blindness cases, and the silent rise of glaucoma (affecting 12 million ...